Form 4: Director Receives Stock Award from Sunshine Biopharma

David Natan, a Director at Sunshine Biopharma Inc., received a stock award of 100,000 shares.

Summary

• David Natan, a Director of Sunshine Biopharma Inc., was granted 100,000 shares of common stock on April 14, 2026.
• This transaction is classified as a stock award, with no purchase price indicated.
• Following this award, Natan beneficially owns 100,000 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock award to a director rather than significant financial or strategic news.

Positives

• Director David Natan received a significant stock award of 100,000 shares, indicating potential alignment of management interests with shareholders.
• The stock award was granted at a price of $0, suggesting it is a form of compensation or incentive.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that stock awards to directors are common in the biopharmaceutical industry as a method to attract, retain, and incentivize key personnel, aligning their interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The stock award may be viewed positively as it aligns director compensation with potential stock appreciation.
• Employees: This filing does not directly impact employees, but it is part of the broader compensation structure for company leadership.
• Management: The award serves as an incentive for the director's continued service and performance.

Key Dates

Keywords

Sunshine Biopharma, SBFM, Form 4, Stock Award, Director, Beneficial Ownership, SEC Filing